155 related articles for article (PubMed ID: 34873228)
1. The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials.
Garofalo C; Capuano I; Pennino L; De Gregorio I; Riccio E; Provenzano M; Crocetto F; Buonanno P; Pandolfo SD; Andreucci M; Pisani A
Sci Rep; 2021 Dec; 11(1):23500. PubMed ID: 34873228
[TBL] [Abstract][Full Text] [Related]
2. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
Gevers TJ; Inthout J; Caroli A; Ruggenenti P; Hogan MC; Torres VE; Nevens F; Drenth JP
Gastroenterology; 2013 Aug; 145(2):357-65.e1-2. PubMed ID: 23665274
[TBL] [Abstract][Full Text] [Related]
3. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials.
Neijenhuis MK; Gevers TJ; Nevens F; Hogan MC; Torres VE; Kievit W; Drenth JP
Aliment Pharmacol Ther; 2015 Sep; 42(5):591-8. PubMed ID: 26129925
[TBL] [Abstract][Full Text] [Related]
5. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
[TBL] [Abstract][Full Text] [Related]
6. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
van Keimpema L; Nevens F; Vanslembrouck R; van Oijen MG; Hoffmann AL; Dekker HM; de Man RA; Drenth JP
Gastroenterology; 2009 Nov; 137(5):1661-8.e1-2. PubMed ID: 19646443
[TBL] [Abstract][Full Text] [Related]
7. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
[TBL] [Abstract][Full Text] [Related]
8. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.
Griffiths J; Mills MT; Ong AC
BMJ Open; 2020 Jan; 10(1):e032620. PubMed ID: 31924636
[TBL] [Abstract][Full Text] [Related]
9. Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.
Gevers TJ; Nevens F; Torres VE; Hogan MC; Drenth JP
Liver Int; 2016 Apr; 36(4):595-602. PubMed ID: 26481454
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.
Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP
BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
Hogan MC; Masyuk TV; Page LJ; Kubly VJ; Bergstralh EJ; Li X; Kim B; King BF; Glockner J; Holmes DR; Rossetti S; Harris PC; LaRusso NF; Torres VE
J Am Soc Nephrol; 2010 Jun; 21(6):1052-61. PubMed ID: 20431041
[TBL] [Abstract][Full Text] [Related]
12. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.
Hogan MC; Masyuk TV; Page L; Holmes DR; Li X; Bergstralh EJ; Irazabal MV; Kim B; King BF; Glockner JF; Larusso NF; Torres VE
Nephrol Dial Transplant; 2012 Sep; 27(9):3532-9. PubMed ID: 22773240
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
Meijer E; Drenth JP; d'Agnolo H; Casteleijn NF; de Fijter JW; Gevers TJ; Kappert P; Peters DJ; Salih M; Soonawala D; Spithoven EM; Torres VE; Visser FW; Wetzels JF; Zietse R; Gansevoort RT;
Am J Kidney Dis; 2014 Mar; 63(3):446-55. PubMed ID: 24342522
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease.
Seliger SL; Abebe KZ; Hallows KR; Miskulin DC; Perrone RD; Watnick T; Bae KT
Am J Nephrol; 2018; 47(5):352-360. PubMed ID: 29779024
[TBL] [Abstract][Full Text] [Related]
16. Effect of everolimus on polycystic liver volume in autosomal dominant polycystic kidney disease.
Zschiedrich S; Budde K; Walz G
Clin Exp Nephrol; 2015 Aug; 19(4):757-8. PubMed ID: 25424440
[No Abstract] [Full Text] [Related]
17. Somatostatin, estrogen, and polycystic liver disease.
Everson GT; Helmke SM
Gastroenterology; 2013 Aug; 145(2):279-82. PubMed ID: 23806538
[No Abstract] [Full Text] [Related]
18. The long-term outcome of patients with polycystic liver disease treated with lanreotide.
Chrispijn M; Nevens F; Gevers TJ; Vanslembrouck R; van Oijen MG; Coudyzer W; Hoffmann AL; Dekker HM; de Man RA; van Keimpema L; Drenth JP
Aliment Pharmacol Ther; 2012 Jan; 35(2):266-74. PubMed ID: 22111942
[TBL] [Abstract][Full Text] [Related]
19. The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression.
Neijenhuis MK; Kievit W; Perrone RD; Sloan JA; Erwin P; Murad MH; Gevers TJG; Hogan MC; Drenth JPH
BMC Nephrol; 2017 May; 18(1):169. PubMed ID: 28545401
[TBL] [Abstract][Full Text] [Related]
20. Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.
Pisani A; Sabbatini M; Imbriaco M; Riccio E; Rubis N; Prinster A; Perna A; Liuzzi R; Spinelli L; Santangelo M; Remuzzi G; Ruggenenti P;
Clin Gastroenterol Hepatol; 2016 Jul; 14(7):1022-1030.e4. PubMed ID: 26844873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]